In less than two months, seasoned investors, influential media, game changing startups and established industry giants will convene at the 42nd Annual JP Morgan Healthcare Conference. Continue Reading
Posts by Kate Coyle
The second quarter of 2022 was the weakest quarter for healthcare and biotech IPOs in more than five years. Some media headlines have predicted that it marked the bottom of the biotech market.
The XBI biotech index fund, which serves as an index for many companies that are eyeing a public debut, peaked in January 2021 followed by a fairly steady 16-month decline. But now, the XBI is on the rise. While it’s too soon to know if the XBI rise that kicked off in July 2022 will continue to mirror the rise that drove its 2021 peak, the climb appears to be signaling a comeback of healthcare and biotech IPOs.
If you’re watching the fund, you might now be considering reviving your plans to take your company public.
After nearly 20 years of working in healthcare communications, the excitement never gets old for me. What’s not to love about an industry that’s critical to life itself, rife with issues and controversy, and delivers a solid dose of the unexpected on a daily basis?
In my mind, a highlight is the problem solving our job requires every day. Whether pursuing an opportunity, managing an issue or leveraging an insight, it’s our responsibility to chart the path forward on behalf of our clients.